It Kills That: Cramer Won’t Recommend Pfizer 7% Yield
Jim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
Indices fluctuate due to price swings in components and shifting sentiment. This short intro outlines the main causes of index volatility.
22,408 articlesJim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
Marvell Technology slides below the $200 level as cloud capex headlines shake sentiment. A KeyBanc upgrade to a $400 ...
A notable new stake in Kyndryl signals growing confidence from a private equity–style shop. This deep dive explains w...
As Flotek prepares for its Q3 2025 earnings, investors will parse management tone, margins, and guidance. This articl...
Anthropic, the Claude-maker, confidentially files to go public, igniting talk of a potential trillion-dollar valuatio...
Insider moves can reveal how company insiders view the path ahead. This guide breaks down what it means when a chief ...
As Guidewire charts its path through cloud adoption and insurer modernization, guidewire (gwre) 2026 earnings become ...
When TPB releases its Q1 2026 numbers, the 2026 earnings call transcript becomes a treasure map for investors. This g...
May brought a sharp drop in oil markets as prices tumbled nearly 20%. This article breaks down what caused the move, ...
SpaceX has fallen roughly a third from its peak, sparking questions about its trajectory. This article outlines four ...
A bold bet on the future of critical minerals. This article breaks down what metals company (tmc) could mean for your...
Warner Bros Discovery's 2026 earnings call transcript offers more than quarterly figures. This analysis breaks down t...